Samsung is embarking on a strategic partnership with Galeon, aiming to enhance the integration of AI-powered ultrasound devices with decentralized health records. This collaboration is set to leverage Galeon’s Electronic Health Record (EHR) system, which is currently operational across 18 interconnected hospitals in Europe, to establish secure, on-chain Web3 features.
As part of this initiative, Samsung will employ its advanced ultrasound technology equipped with cutting-edge AI capabilities to feed data directly into Galeon’s EHR. This integration promises to streamline clinical workflows, enabling healthcare providers to update and interpret ultrasound images in real time, all while ensuring patient privacy is maintained.
Benjamin Tarter, Head of Women’s Health at Samsung France, expressed excitement about the alliance, stating, “We are incredibly proud of this partnership and ready to disrupt the health market together.” The partnership aims to harness Web3 principles to reduce the administrative burden on hospitals and improve diagnostic accuracy and care decisions.
Galeon will play a crucial role in managing the clinical workflows and quality control of AI training. The platform allows hospitals to train AI models using anonymized incoming datasets, ensuring that institutions retain control over their data while benefiting from transparent model training enhanced by real-world information. As Samsung’s devices become interconnected, Galeon can provide more precise AI training, delivering immediate, structured records that facilitate preventive healthcare at scale.
Dr. Loïc Brotons, CEO of Galeon, highlighted the significance of this partnership, noting, “Samsung’s device leadership meets our in-production EHR and decentralized AI stack to provide what the industry has been missing.” He emphasized the initiative’s purpose to link AI imaging with real-time hospital workflows, supported by community-governed research, to accelerate medical discoveries while preserving patient privacy.
The partnership envisions that Galeon’s Atlantis platform will manage the collected research data, utilizing the native GALEON token. This innovative approach allows over 100,000 supporters to participate in the anonymized data process through Galeon DAO, enabling them to vote on funding for medical studies. Furthermore, this collaboration aligns with the Web3 trend of Decentralized Science (DeSci), striving to connect real-world data directly with patient needs.
The Atlantis platform seeks to simplify participation and governance in decentralized science, combining insights from over 10,000 caregivers and a growing community of users and investors. By tokenizing real-time clinical practice and research data, Galeon aims to unlock significant value in the healthcare landscape.
From 2025 onward, this partnership is poised to reinvigorate the decentralized science narrative, engaging with a sector valued at close to $1 billion. The principles of DeSci focus on tokenizing scientific data and incentivizing research through investor participation and governance, marking Samsung’s collaboration as one of the most consequential real-world partnerships within this evolving space.
